GlassScriptPhysician profile
Gerard A Delgrippo
NPI 1447233234
$963.03
in general payments reported to CMS, 2019-2025
19 companies · $535 in 2025
The $535 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.84 · 2020: $23.21 · 2021: $71.12 · 2022: $108 · 2023: $68.01 · 2024: $142 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $197.55 | 2021-2025 | Ubrelvy, Vraylar |
| Novo Nordisk INC | $121.24 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $79.10 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $64.48 | 2025 | Airsupra |
| Inspire Medical Systems, INC. | $54.05 | 2025 | Inspire |
| Cranial Technologies, INC | $51.91 | 2023-2025 | Doc Band |
| Abbott Laboratories | $48.22 | 2022-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $43.21 | 2025 | Spravato |
| Merck Sharp & Dohme LLC | $43.20 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company LTD. | $40.00 | 2022 | |
| Lilly USA, LLC | $39.72 | 2020-2025 | Zepbound, Mounjaro |
| Amgen INC. | $28.00 | 2020-2024 | Prolia, Evenity |
| Tms Neurohealth Centers INC. | $27.16 | 2025 | Tms Neurohealth Centers INC. |
| Exact Sciences Corporation | $26.26 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $24.18 | 2025 | Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $24.18 | 2025 | Zurzuvae |
| Allergan, INC. | $17.68 | 2021 | |
| Pfizer INC. | $17.28 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $15.61 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Delgrippo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.